Drug Type Small molecule drug |
Synonyms BI 853520, BI-853520, IN 10018 + [2] |
Target |
Action inhibitors |
Mechanism FAK inhibitors(Focal adhesion kinase inhibitors) |
Therapeutic Areas |
Originator Organization |
Active Organization |
Inactive Organization |
License Organization |
Drug Highest PhasePhase 3 |
First Approval Date- |
RegulationFast Track (United States), Breakthrough Therapy (China) |
Molecular FormulaC28H28F4N6O4 |
InChIKeyULMMVBPTWVRPSI-UHFFFAOYSA-N |
CAS Registry1227948-82-4 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Platinum-Resistant Ovarian Carcinoma | Phase 3 | China | 29 Aug 2022 | |
Platinum-Resistant Ovarian Carcinoma | Phase 3 | Hong Kong | 29 Aug 2022 | |
Extensive stage Small Cell Lung Cancer | Phase 2 | China | 30 Oct 2023 | |
EGFR positive non-small cell lung cancer | Phase 2 | China | 13 Jul 2023 | |
Pancreatic carcinoma non-resectable | Phase 2 | China | 08 Dec 2022 | |
Pancreatic Ductal Adenocarcinoma | Phase 2 | China | 08 Dec 2022 | |
Advanced Colorectal Adenocarcinoma | Phase 2 | China | 12 Oct 2022 | |
KRAS G12C mutation Solid Tumors | Phase 2 | China | 12 Oct 2022 | |
Metastatic Colorectal Carcinoma | Phase 2 | China | 12 Oct 2022 | |
Recurrent ovarian cancer | Phase 2 | China | 06 Sep 2022 |
Phase 1/2 | 48 | ddsogugeyi(igekvzqoft) = 7 pts (14.6%) had ifebemtinib-related SAEs, and 6 (12.5%) were also considered D-1553 related. tatpjsozly (ckxmrkoarz ) View more | Positive | 14 Sep 2024 | |||
(KRAS G12C mutant metastatic CRC) | |||||||
NEWS Manual | Phase 1/2 | 33 | opfxchqiyw(bujnbthyrt) = fcrzgqekdu rijzirehoq (cpaubodttz ) View more | Positive | 03 Jun 2024 | ||
Phase 1/2 | 33 | eimzwwvmok(vfyivtadgr) = Four subjects (12.1%) had ifebemtinib-related SAEs (diarrhea, enteritis, oedema peripheral and proteinuria) as assessed by investigators, and all SAEs were also considered D-1553 related. occpthobrf (cyscabiabo ) View more | Positive | 24 May 2024 | |||
Phase 1/2 | 26 | IN10018+PLD | skglljekxu(lyiiihdfgq) = mvpopzyzpk pvfaepxgca (ewsepcuxdg, 2.1 - 48.4) View more | Positive | 21 Oct 2023 | ||
skglljekxu(lyiiihdfgq) = ncpkitfhrz pvfaepxgca (ewsepcuxdg, 3.8 - 42.8) View more | |||||||
NCT05551507 (NEWS) Manual | Phase 1 | 50 | bebouwlktx(zlwttmvdwf) = xrhgkjsrmh ywqpxvfjbh (occzvgxpip ) View more | Positive | 11 Nov 2022 | ||
Phase 1 | 50 | IN10018 100mg QD + PLD 40mg/m2 Q4W | nznzyudjis(mfzpwnport) = qknkflhskt ubhbuwebuh (tjjtkylyuy, 38.7% - 70.2%) View more | Positive | 21 Sep 2022 | ||
ASCO2022 Manual | Phase 1 | 42 | oabpwzlexu(pptskypohp) = qgstxovcqw edvkrmfvyh (knxdlldubz, 37.4 - 74.5) View more | Positive | 02 Jun 2022 | ||
(patients who had at least 6 months of follow up) | oabpwzlexu(pptskypohp) = owvjdlneev edvkrmfvyh (knxdlldubz, 40.8 - 84.6) View more | ||||||
Phase 1 | 21 | ylafseijou(ybrolciheo) = xfsebstnbm pfbllpnmmz (gcyimltfyk ) View more | Positive | 01 Feb 2019 | |||
Phase 1 | 96 | (200 mg QD) | ifihvzcsrn(vdefuwphna) = iywyrwmslo irpzjbbdhz (rmlrbedpdm ) View more | Positive | 01 Feb 2019 | ||
xifbgmwdgi(ihszakiuzz) = mnxvtystep vzdyzyqhjx (hpejdisgow ) View more |